Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company is focused on providing innovative treatments for diseases that have limited or no treatment options. Avalo’s pipeline includes AVTX-002, a fully human anti-LIGHT monoclonal antibody that is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. AVTX-007, a fully human Anti-IL-18 monoclonal antibody is also under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis. Avalo’s products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG.

Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo’s mission is to bring innovative and transformative treatments to patients with limited or no treatment options. The company has established a strong network of strategic collaborations and partnerships with leading pharmaceutical companies, academic institutions, and research organizations.

Avalo has a highly experienced team of scientists and executives with expertise in drug discovery, development, and commercialization. The company is led by CEO, Dr. Mark Currie, who has more than 25 years of experience in the pharmaceutical industry. He has held executive-level positions in both large and small biopharmaceutical companies, and has extensive experience in the development and commercialization of innovative drugs.

Avalo Therapeutics, Inc. is dedicated to developing and commercializing targeted therapeutics to address unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. The company is focused on bringing novel treatments to patients with limited or no treatment options. Avalo’s pipeline includes multiple clinical-stage assets across a range of therapeutic areas, including AVTX-002, AVTX-007, AVTX-801, and AVTX-803. The company is committed to advancing its pipeline of therapeutics and delivering innovative treatments to patients in need.